Although the influenza vaccine is recommended for all children aged ≥6 months, <45% of young children are fully vaccinated and the health care burden of influenza is considerable.
Currently available evidence indicates the safety of the U.S. childhood immunization schedule, with no indication of major safety concerns.
Pandemic influenza A (H1N1) infection in pregnancy is associated with an increased risk of fetal death, and vaccination is associated with a non-significant reduction in the risk of fetal death.
The majority of biologics approved since 1997 include pediatric information in their labeling and have been studied in pediatric trials.
Among children aged 12-35 months, receipt of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in the arm is associated with a significantly increased risk of medically attended local reactions.
Flu activity remains elevated, according to FluView, a weekly influenza surveillance report prepared by the Influenza Division of the U.S. Centers for Disease Control and Prevention; however, the annual flu vaccine is moderately effective at preventing the disease.
The national prevalence of three doses of human papillomavirus (HPV) vaccination among adolescent girls is about 32%, and incidence rates for some HPV-associated cancers are increasing.
HIV-infected adults achieve higher rates of seroprotection when immunized with a high-dose of the influenza trivalent vaccine compared to the standard dose.